

## **AcmeCRO Goes Public**

**By Norman M. Goldfarb**

AcmeCRO, an international contract research organization, completed a surprise initial public offering today, April 1<sup>st</sup>, 2013 on the XcloudXchange. In the offering, 414,141 common shares were sold for a total of \$1.72 billion. "We wanted to be the first into a brisk market," said Dolores Formes, AcmeCRO's chief financial officer, "and I'd have to say the wind is at our backs."

The purpose of the offering was to provide working capital, pay down debt, provide returns to investors, and finance pending acquisitions of 92 companies to create a "one-stop shop" for clinical research. "Like my daddy says, 'go big or go home,'" explained Tex Acme, AcmeCRO's founder and chairman.

The offering provides liquidity to investors, employees and former study subjects who accepted stock options in lieu of cash stipends. "It's an honor to reward the confidence of so many great friends who have supported our efforts to cure serious diseases, save lives, and put some coin in their pockets," said Owen Nomoray, AcmeCRO's chief executive officer.

"We've been flying under the radar so long, my knees are green," said Skyler Stelimith, AcmeCRO's vice president of marketing. "We have kept a low profile until now, but you can expect to hear more from us in the near future," she continued, "Our first priority will be to ramp up acquisitions. Right now, I'm thinking about a sweet imaging lab in Bessarabia that we can't wait to get our hands on."

According to Takien Visprisi, a prominent financial analyst, "This offering caught everyone by surprise. I guess someone should start paying attention to the clinical research space."

"The clinical research industry is finally getting its act together. My years of constant heckling are finally paying off," enthused Al Wasonotak, until now a relentless industry critic. "It's a bright day for our planet."

"We continue to be awed by the selfless contributions AcmeCRO clinical researchers make to the public welfare, at no small personal sacrifice to themselves. I thank them, my children thank them, and my grandchildren will thank them too," said Vera Onyosid, Executive Director of United Patient Advocacy Groups, an association based in Washington, DC.

### **Author**

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information services. Contact him at 1.650.465.0119 or [ngoldfarb@firstclinical.com](mailto:ngoldfarb@firstclinical.com).